Genprex to Launch Investors Website and Increase Emphasis on Investor Relations in 2019

Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it will be increasing its investor relations efforts in 2019, spearheaded by the launch of an innovative corporate website with more robust investor resources, including the company’s presentations, stock charts and integrated quotes, SEC filings, news, media coverage, and tailored email newsletters, among other advanced communication tools. As part of today’s announcement, investors already have the ability to receive all news regarding Genprex straight to their inbox by signing up for the company’s communication list at https://www.genprex.com/investors/email-alerts/.

In addition to the new investor relations initiatives, Genprex will also be retaining the services of expert media relations and public relations firms with the express purpose of increasing the quantity and improving the quality of investor communications. Genprex also plans to use modern tools like social media for greater distribution of news and company announcements. According to Genprex CEO Rodney Varner, engagement and outreach with investors will be among the company’s top priorities in 2019.

“We’re extremely excited about the added emphasis on investor communications and relations in the new year,” said Varner. “We believe that the drug candidates that we are working to develop every day at Genprex are groundbreaking and we recognize the importance in keeping investors abreast of our team’s initiatives and successes. With the new website and email newsletters we will be launching, we intend to provide to current and potential investors unprecedented insight into what is happening at Genprex as we continue to work at the forefront of the new age of immunogene therapy cancer treatments.”

The company’s new investor relations initiatives come on the heels of months of promising developments at Genprex.

In October, Jan Stephens, RN, joined the company’s Cambridge, Massachusetts office as Genprex’s new Vice President of Clinical Operations, bringing with her nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stephens joined the company to help support the various clinical development programs for Genprex’s proprietary immunogene therapy, Oncoprex™.

In addition to adding Stephens to its clinical leadership team, Genprex also entered into a significant agreement with The University of Texas MD Anderson Cancer Center to extend two option agreements between Genprex and MD Anderson pertaining to the use of TUSC2, the active agent in Oncoprex.

Forward-Looking Statements

Statements contained in this press release that are not statements of historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because these statements are subject to risks and uncertainties, the actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of TUSC2 on cancer, the services we expect to receive from media relations and public relations firms and the effect of those services and statements about Genprex’s business plans. Risks that contribute to the uncertain nature of the forward-looking statements include: the presence and level of TUSC2’s effect on cancer; the ability of media relations and public relations firms to provide value to the company and the company’s ability to utilize those services; Genprex’s ability to negotiate and execute final technology license agreements under the extended options with MD Anderson; and the nature and scope of protection ultimately provided under any of the licensed patents and patent applications should such technology license agreements be executed. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Genprex’s filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Genprex does not undertake any obligation to update these statements to reflect any events that occur or facts that exist after the date on which the statements were made.

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. Visit the company’s web site at http://www.genprex.com or follow Genprex on Twitter at https://twitter.com/genprex and Facebook at https://www.facebook.com/genprexinc/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181212005202/en/